Search
News & Events
Bupa pledges half a million dollars to end rheumatic heart diseaseResearchers will extend a unique community-led project to end rheumatic heart disease in Aboriginal communities, thanks to nearly half a million dollars in funding from Bupa.
News & Events
RHD a notifiable conditionWestern Australian doctors are now required by law to report all cases of rheumatic heart disease.
News & Events
Researchers share their expertise with the community in CockburnResearchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.
News & Events
Warm Welcome for the Neonatal Infection and Immunity TeamClinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.
News & Events
Visit from On Track Watch Community Researchers helps build a pathway of looking at two different culturesFor Aboriginal Community Researchers Minitja Marawili and Yunutju Gondarra, the work of the END RHD CRE is deeply personal.
News & Events
Laqueisha's story: living with RHDLaqueisha was just five years old when she was diagnosed with rheumatic heart disease and sent on a 5,000km return trip to Perth for major heart surgery.
Research
Outcomes of latent rheumatic heart disease: External validation of a simplified score in patients with and without secondary prophylaxisSecondary antibiotic prophylaxis reduces progression of latent rheumatic heart disease (RHD) but not all children benefit. Improved risk stratification could refine recommendations following positive screening. We aimed to evaluate the performance of a previously developed echocardiographic risk score to predict mid-term outcomes among children with latent RHD.
Research
Left ventricular remodelling in rheumatic heart disease – trends over time and implications for follow-up in childhoodRheumatic heart disease (RHD) is the most common form of acquired heart disease worldwide. In RHD, volume loading from mitral regurgitation leads to left ventricular (LV) dilatation, increased wall stress, and ultimately LV dysfunction. Improved understanding of LV dynamics may contribute to refined timing of intervention.
Research
Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart diseaseRegular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.
Research
The evidence that rheumatic heart disease control programs in Australia are making an impactRheumatic heart disease (RHD) comprises heart-valve damage caused by acute rheumatic fever (ARF). The Australian Government Rheumatic Fever Strategy funds RHD Control Programs to support detection and management of ARF and RHD. We assessed epidemiological changes during the years of RHD Control Program operation.